MIP Diagnostics develop and manufacture molecularly imprinted polymers (nanoMIPs) that act as synthetic alternatives to antibodies for IVD and other industries.
Employees: 11-50
Total raised: $8.87M
Founded date: 2015
Funding Rounds 1
| Date | Series | Amount | Investors |
| 26.02.2024 | Series A | $8.87M | - |
Mentions in press and media 8
| Date | Title | Description | Source |
| 26.02.2024 | MIP Discovery closes £7M Series A financing to drive commerc... | - | calculusca... |
| 21.02.2024 | MIP Discovery Secures £7M Series A Funding for Cell and Gene... | MIP Discovery, a UK-based developer of synthetic affinity reagents for cell and gene therapies, has ... | parsers.vc... |
| 20.02.2024 | MIP Discovery closes £7M Series A financing to drive commerc... | Company’s synthetic affinity reagents are antibody alternatives designed to advance the speed, safet... | cambridgen... |
| 19.02.2024 | MIP Discovery Closes £7M Series A Financing | MIP Discovery, a Bedford, Bedfordshire, UK-based developer of non-biological affinity reagents for c... | finsmes.co... |
| 04.04.2023 | MIP Discovery announces drugs of abuse reagent launch | Vial of norfentanyl affinity reagents from MIP Discovery New MIP Discovery Identity Novel nanoMIP af... | einpresswi... |
| 24.05.2022 | MIP Discovery Adopts the Fida 1 Platform | The FIDA technology enables MIP Discovery to offer Molecularly Imprinted Polymers of unmatched quali... | einpresswi... |
| 18.05.2022 | Rapidly growing nanotechnology firm launches new identity as... | New MIP Discovery Identity MIP Diagnostics, a leading UK nanotechnology firm has today rebranded to ... | einpresswi... |
| - | MIP Discovery | “Cell and gene therapies offer exciting new possibilities for curing diseases and improving quality ... | fastfounde... |